{Reference Type}: Journal Article
{Title}: Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods.
{Author}: Cheng Y;Song Z;Chen J;Tang Z;Wang B;
{Journal}: Heliyon
{Volume}: 10
{Issue}: 4
{Year}: 2024 Feb 29
{Factor}: 3.776
{DOI}: 10.1016/j.heliyon.2024.e25895
{Abstract}: Oral squamous cell carcinoma (OSCC) affects a large number of individuals worldwide. Despite advancements in surgery, radiation, and chemotherapy, satisfactory outcomes have not been achieved. In recent years, the success of drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to breakthroughs in cancer treatment, but systematic summaries on their effectiveness against OSCC are lacking. This article reviews the latest research on the PD-1/PD-L1 pathway and the potential of combination therapy based on this pathway in OSCC. Further, it explores the mechanisms involved in the interaction of this pathway with exosomes and protein-protein interactions, and concludes with potential future OSCC therapeutic strategies.